Appendix 2. Included references details

Author, Year (Country) Algaert, 2004 (FIS) (a); Algaert, 2004 (FIS) (a); Author, Year (Country) Au	
Alegret, 2004 (ES) (a)	
Alegred, 2004 (ES) (a)	
Alug. 2011 (TR) (a.e.) Auclair-Ouellet, 2011 (CA) (a.h) Berney, 2002 (CHCA) (a.h) Daniele, 2003 (TT) (a.e.) Daniele, 2003 (TT) (a.e.) De Gaspari, 2006 (TD) (a.e.) De Gaspari, 2006 (TR) (a.e.) Dujardin, 2004 (FR.CA.BE) (a.A.) Fassina, 2010 (TR) (a.e.) A X Y Y A san, 6an, 1y, 19 July and a control of the control	
Auclair-Ouellet, 2011 (CA) (a,l)	
Berney, 2002 (CH/CA) (a,b)	
Bordini, 2007 (US) (a)	
De Gaspari, 2006 (IT) (a)	
Denheyer, 2009 (CA) (a)	y y
Derost, 2007 (FR) (a,g,i)	y
Drapier, 2005 (FR) (a)	y
Dujardin, 2004 (FR/CA/BE) (a,A) Fasano, 2010 (IT) (a) Funkiewiez, 2006 (FR/UK) (a,i,o) Kervais-Bernard, 2009 (FR) (a) Heo, 2008 (KR) (a) Kalteis, 2006 (AT) (a,e,b,D) Kalteis, 2006 (AT	y
Fasano, 2010 (IT) (a)	y
Funkiewiez, 2006 (FR/UK) (a,i,o)	y
Heo, 2008 (KR) (a)	y
Houeto, 2002 (FR)	y
Houeto, 2006 (FR) (a)	y
Huebl, 2011 (DE/UK) (n)	y
Kaiser, 2008 (AT) (a,e,h,D) x x x x x x x x x x x x x x x x x x x	y
Kalteis, 2006 (AT) (a,e,D)	у
Krack, 2003 (FR) (a) x	
Krause, 2004 (DE) (k) x x x y y 30m Lhommée, 2012 (FR) (a,j,l) x(c) x x x(c) x x(c) x x(c) x x(c) x y y y y 1y Martinez-Martin, 2002 (ES) (a) x x x x y y 6m Merello, 2008 (AR) (a) x x x y y 6m, ly Nazzaro, 2011 (US) (c) x x x y y 1y Ory-Magne, 2007 (FR) (a,e) x x x y y y 1y, 2y Perroi, 2006 (FR) (c) x x x y y y y y y y y y 1y Saint-Cyr, 2000 (US/CA) (a,f) x x x y	
Lhommée, 2012 (FR) (a,j,l) x(c) x	
Martinez-Martín, 2002 (ES) (a) x x √ √ 6m Merello, 2008 (AR) (a) x x √ ✓ 6m, 1y Nazzaroz, 2011 (US) (c) x x √ ✓ 1y Ory-Magne, 2007 (FR) (a,e) x √ ✓ 1y, 2y Perozzo, 2001 (IT) (d) x x √ ✓ 6m Perriol, 2006 (FR) (c) x x √ ✓ 1y Saint-Cyr, 2000 (US/CA) (a,f) x x √ ✓ 6m Schadt, 2006 (US) (a,hm) x x ✓	
Merello, 2008 (AR) (a)	_
Nazzaro, 2011 (US) (c)	
Perozzo, 2001 (IT) (d) x	
Perriol, 2006 (FR) (c)	
Saint-Cyr, 2000 (US/CA) (a,f) x	
Schadt, 2006 (US) (a,h,m) x	
	n
Schoenberg, 2008 (US) (d) X X Y	
Simuni, 2002 (US) (d) x 4 6m	
Temel, 2007 (NL) (b,g) x / 3m, 1y	
Tröster, 2003 (US) (a)	-
Witjas, 2007 (FR) (a) x / 1y Yamada, 2006 (JP) (a,j) x / 3 m	
Zibetti, 2007 (IT) (a,e) x 1y, 2y	
Zibetti, 2009 (IT) (a,e,E) x	
Zibetti, 2011 (IT) (a,e,E) x x x x x x x x x x x x x x x x x x x	
Morrison, 2004 (US) (a,j) x	2
Oyama, 2011 (JP) (a,f,O)	2
Smeding, 2006 (NL) (b) x x x √ ✓ 6m Wang, 2009 (CN) (a,e,G,H) x(C) x √ ✓ Iw, 2m, 5m, 11m	
Witt, 2008 (DE/AT) (b,B) x x x x x x x x x x 6 m	2
York, 2008 (US) (a) x x x x x x x x x x x x x x x x x x x	2
Capecci, 2005 (IT) (a,e) x / 1y, 2y	3
Drapier, 2006 (FR) (a,e) x x x x x 3m, 6m	3
Péron, 2010 (FR/CH) (a) x x x(c) / 35m Montel, 2008 (FR) (a) x x(c) / 1y	1,3 2,3
Montel, 2008 (FR) (a)	3
Castein, 2000 (11) (a) x	3
Fields, 1999 (US) (n,M,N) x x x x x 3 m	
Ghika, 1998 (CH) (d) x 3m	
Loher, 2002 (CH/DE) (q) x 3m, 1y	-
Burchiel, 1999 (US)* x / / / 1y Weaver, 2009 (US)* x / / / 6m	2
Weaver, 2009 (US)* x Ardouin, 1999 (FR) (a,g,K,L) x J √ √	4
Follett, 2010 (US) (a,m,p) x	4
Rothlind, 2007 (US) (a) x	4
Volkmann, 2001 (DE) (a) x 5 6m, 1y	4

Psychometric instruments used are highlighted with "x". Stimulation target is marked with " \checkmark " in "STN" and/or "GPi" columns. Follow-up studies have " \checkmark " in the respective column and

comparison studies are codified by 1 to 4 so different comparators can be distinguished. Grey shading denotes references excluded from analysis (non-comparable data).

Notes: 1 to 4 corresponds to comparators coding; 1: healthy control group, 2: medical treatment control group, 3 eligible for surgery control group and 4: GPi comparison group; * references with STN and GPi data not discriminated: no further analysis; (a) original data is pre M(SD) and post M(SD): changeM calculated as (postM - preM); changeSD calculated as $\sqrt{\text{[(preSD2 + posSD2 - 2)]}}$ x r x preSD x posSD) / n]; (b) original data is pre M(SD) and change M(SD); (c) original data not quantitative/comparable (percentage of patients): no further analysis; (d) original data not quantitative/comparable (qualitative description): no further analysis; (e) within each period of time, the longest follow-up was selected for the analysis; (f) "x to y months" type follow-up: y months assumed; (g) original data reported by groups; separately considered for the analysis; (h) original data reported on total sample and by groups: total sample considered; (i) SD calculated from SE as (SE x \sqrt{n}); (i) original data reported in on and off state: only on considered; (k) original data not quantitative/comparable (no dispersion measure): no further analysis; (1) mean (SD) assumed; (m) SD calculated from 95% CI as [(upper limit - lower limit) / 3.92] x \sqrt{n} ; (n) original data reported individually: preM(SD) and changeM(SD) calculated; (o) graphical data; (p) intention-to-treat analysis; (q) original data not quantitative/comparable (percentage of change): no further analysis; (A) cognitive outcomes compared with control group; depression and anxiety assessed only in patients; so, follow-up STN-DBS study design assumed; (B) "positive change scores indicate clinical improvement; data are (...) mean (SD) (...) for changes between baseline (before DBS) and 6 months": - changeM assumed; (C) HDRS not consecutively assessed: "depression was evaluated (...) using the Self-Rating Depression Scale (...); every patient whose SDS score showed a mild depression, or more, was evaluated again (...) using the Hamilton Depression Scale"; (D) partial duplicates: BDI, POMS-d, STAI-s, STAI-t, SCL-90-R-d and SCL-90-R-a data from Kaiser, 2008; BRMES and HAMA data from Kalteis, 2006; (E) partial duplicates:

3 years follow-up data from Zibetti, 2009; 9 years follow-up data from Zibetti, 2011 (and the respective preoperative data for each one); (F) data from n=20 (whole sample) and from n=9 (18 months follow up sample); evaluation moments at 3, 6, 12 and 18 months; n=20 preoperative data considered for short-term follow-up analysis; n=9 preoperative data considered for mid-term follow-up analysis; (G) stimulation device was turned on 4 weeks after the surgery: postoperative moments converted to post-DBS moments by subtracting 1 month; (H) "depression severity index" = "accumulative scores of each item"/"maximum scores of the scale": mean x 80 and SD x 80 assumed; (I) "the assessments took place (...) 12 months (...) later, with the exception of the cognitive status, which was controlled 3 months after surgery"; "outcome measures" = "motor function" + "cognitive status" + "psychiatric history" + "mood and behavioral modifications: ardouin scale" + "acute non-motor fluctuations": 1 year follow up assumed to mood evaluation; (J) results separated by groups "identical", "ameliorated" and "aggravated": not comparable with other studies; (K) Partial duplicate: 4 groups: STN versus GPI and Paris versus Grenoble: GPI in Grenoble, GPI versus STN comparison in Grenoble, STN in Paris, GPI in Paris and GPI versus STN comparison in Paris included; STN in Grenoble duplicated; (L) 4 groups: STN versus GPI and Paris versus Grenoble: only 57 in a total of 62 patients performed BDI assessment and the distribution by groups was not indicated: total n assumed for each group. (M) staged DBS; evaluation times were "1 month before first surgery, 2 months following first surgery (unilateral), and 3 months following second surgery (bilateral)": 3 months follow-up assumed; (N) "Test-retest interval was about 3 months between baseline and post-unilateral electrode placement evaluation, and 4 months between post-unilateral and post-bilateral electrode placement evaluations. This occurred with the exception of one patient who on separate occasions had the lead and pulse generator repositioned following bilateral operation, resulting in a 22-month lapse between neuropsychological assessments after first and second DBS electrode placement.": global 3 months follow-up assumed; (O) pre- and postoperative evaluations performed in patients group; only 1 evaluation in control group: postoperative cross-sectional analysis assumed.

Test-retest coefficient (r) was 0,66 for BAI⁸³, 0,64 (short term) and 0,75 (mid- and long- term) for BDI⁸¹, 0,79 for BSI-a⁸⁵, 0,84 for BSI-d⁸⁵, 0,94 for GDS⁸⁴, 0,98 for HAD-a⁸⁸, 0,99 for HAD-d⁸⁸, 0,87 for HDRS⁷⁹, 0,56 for MADRS⁸⁰, 0,4 for STAI-s⁹⁰, 0,86 for STAI-t⁹⁰ and 0,651 for UPDRS I,3⁸⁶. 0,98 assumed for BRMES⁸⁷. 0,75 assumed for POMS-d⁸⁹. Conservative value of 0,56 was assumed for SCL-90-R-d and Zung-d. Conservative value of 0,4 was assumed for AMDP-AT, BAS, HAMA, SCL-90-R-a and Zung-a.

Abbreviations: in "follow-up" column, w, m and y refers to weeks, months and years, respectively; pre: preoperative data; post: postoperative data; M: mean; SD: standard deviation; SE: standard error; 95%CI: 95% confidence interval; r: test-retest correlation coefficient; n: sample size; "change" refers to the postop - preop temporal change; "difference" refers to the STN - comparison group difference; AMDP-AT: association for methodology and documentation In psychiatry, anxiety part; Ardouin-a and Ardouin-d: "anxiety" and "depressive mood" items of the Ardouin scale, respectively; BAI: Beck anxiety inventory; BAS: brief scale for anxiety; BDI: Beck depression inventory; BRMES: Bech-Rafaelsen Melancholia Scale; BSI-a and BSI-d: anxiety and depression scales of the brief symptom inventory, respectively; GDS: geriatric depression scale; GPi: globus pallidus, pars interna; HAD-a and HAD-d: anxiety and depression parts of the hospital anxiety and depression scale, respectively; HAMA: Hamilton anxiety scale; HDRS: Hamilton depression rating scale; IOWA-a and IOWA-d: anxiety and depression parts of the IOWA scales of personality change, respectively; MADRS: Montgomery-Asberg depression rating scale; MINI-a and MINI-d: "general anxiety"/"anxiety disorders" and "major depression episode/disorder" items of the "mini international neuropsychiatric interview, respectively; NMSQuest-a and NMSQuest-d: items "anxiety" and "feeling sad" of the non motor symptom questionnaire, respectively; POMS-d: profile of mood states, depression domain; SCL-90-R-a and SCL-90-R-d; anxiety and depression domains of the symptom checklist-90-revised; STAI-s and STAI-t: state and trait (respectively) anxiety inventory; STN: subthalamic nucleus; UPDRS I,3: unified parkinson's disease rating scale,

part I, item 3 "depression"; Zung-a and Zung-d: Zung self-rating anxiety and depression scales, respectively. Country abbreviations according to ISO 3166-1 decoding table.